Literature DB >> 16078039

Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer.

J-J Yeh1, N-Y Hsu, W-H Hsu, C-H Tsai, C-C Lin, J-A Liang.   

Abstract

The aim of this study was to investigate the expression of P-glycoprotein (Pgp), multidrug resistance-related protein-1 (MRP1), and lung resistance-related protein (LRP) in response to chemotherapy in untreated small cell lung cancer (SCLC). Immunohistochemical analyses were performed on multiple nonconsecutive sections of biopsy specimens to detect Pgp, MRP1, and LRP expression in 40 patients with SCLC before chemotherapeutic induction. Response to chemotherapy was evaluated by clinical and radiological methods. The patients were divided into a good response group (n = 20) and a poor response group (n = 20). No significant differences in prognostic factors (Karnofsky performance status, tumor size, or tumor stage) were found between the two groups of patients. The difference in positive Pgp and MRP1 expressions between the good and poor response groups was significant. However, the difference in LRP expression was not significant. We conclude that chemotherapy response of patients with SCLC was related to either Pgp or MRP1 but not LPR expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16078039     DOI: 10.1007/s00408-004-2532-1

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  15 in total

1.  Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance.

Authors:  R J Scheper; H J Broxterman; G L Scheffer; P Kaaijk; W S Dalton; T H van Heijningen; C K van Kalken; M L Slovak; E G de Vries; P van der Valk
Journal:  Cancer Res       Date:  1993-04-01       Impact factor: 12.701

2.  Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues.

Authors:  A M Dingemans; J van Ark-Otte; P van der Valk; R M Apolinario; R J Scheper; P E Postmus; G Giaccone
Journal:  Ann Oncol       Date:  1996-08       Impact factor: 32.976

3.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

4.  Multidrug resistance-associated protein (MRP) gene expression in human lung cancer.

Authors:  F Narasaki; I Matsuo; N Ikuno; M Fukuda; H Soda; M Oka
Journal:  Anticancer Res       Date:  1996 Jul-Aug       Impact factor: 2.480

Review 5.  Multidrug resistance and its reversal.

Authors:  M Volm
Journal:  Anticancer Res       Date:  1998 Jul-Aug       Impact factor: 2.480

6.  Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression.

Authors:  T-C Hsia; C-C Lin; J-J Wang; S-T Ho; A Kao
Journal:  Lung       Date:  2002       Impact factor: 2.584

7.  The drug resistance-related protein LRP is the human major vault protein.

Authors:  G L Scheffer; P L Wijngaard; M J Flens; M A Izquierdo; M L Slovak; H M Pinedo; C J Meijer; H C Clevers; R J Scheper
Journal:  Nat Med       Date:  1995-06       Impact factor: 53.440

8.  Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.

Authors:  M A Izquierdo; R H Shoemaker; M J Flens; G L Scheffer; L Wu; T R Prather; R J Scheper
Journal:  Int J Cancer       Date:  1996-01-17       Impact factor: 7.396

9.  To predict response chemotherapy using technetium-99m tetrofosmin chest images in patients with untreated small cell lung cancer and compare with p-glycoprotein, multidrug resistance related protein-1, and lung resistance-related protein expression.

Authors:  Tsung-Huai Kuo; Feng-Yu Liu; Cheng-Yen Chuang; Hurng-Sheng Wu; Jhi-Joung Wang; Albert Kao
Journal:  Nucl Med Biol       Date:  2003-08       Impact factor: 2.408

10.  Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.

Authors:  J Kreisholt; M Sorensen; P B Jensen; B S Nielsen; C B Andersen; M Sehested
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

View more
  12 in total

Review 1.  Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.

Authors:  Laleh Amiri-Kordestani; Agnes Basseville; Karen Kurdziel; Antonio Tito Fojo; Susan E Bates
Journal:  Drug Resist Updat       Date:  2012-03-29       Impact factor: 18.500

2.  Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells.

Authors:  Abraham H Abouzeid; Niravkumar R Patel; Can Sarisozen; Vladimir P Torchilin
Journal:  Pharm Res       Date:  2014-02-13       Impact factor: 4.200

3.  Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.

Authors:  Wentao Li; Baoping Zhai; Hui Zhi; Yuhong Li; Linjiao Jia; Chao Ding; Bin Zhang; Wei You
Journal:  Tumour Biol       Date:  2014-06-04

Review 4.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

5.  Teratoma with malignant transformation: a case report with pathological, cytogenetic, and immunohistochemistry analysis.

Authors:  Jue Wang; Syed A Jaffar Kazmi
Journal:  Sarcoma       Date:  2011-06-09

6.  Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy.

Authors:  Sherri Z Millis; Samuel Ejadi; Michael J Demeure
Journal:  Biomark Cancer       Date:  2015-12-17

7.  Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma.

Authors:  Rolf Warta; Dirk Theile; Carolin Mogler; Esther Herpel; Niels Grabe; Bernd Lahrmann; Peter K Plinkert; Christel Herold-Mende; Johanna Weiss; Gerhard Dyckhoff
Journal:  PLoS One       Date:  2014-10-02       Impact factor: 3.240

8.  Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.

Authors:  Huanxin Liu; Jie Huang; Juan Peng; Xiaoxia Wu; Yan Zhang; Weiliang Zhu; Linlang Guo
Journal:  Mol Cancer       Date:  2015-03-12       Impact factor: 27.401

9.  Genomic analysis of drug resistant small cell lung cancer cell lines by combining mRNA and miRNA expression profiling.

Authors:  Yitian Chen; Xiang Yang; Yichen Xu; Jiongrui Cao; Longbang Chen
Journal:  Oncol Lett       Date:  2017-03-31       Impact factor: 2.967

10.  Cyclosporine A enables vincristine-induced apoptosis during reversal of multidrug resistance phenotype in chronic myeloid leukemia cells.

Authors:  Paloma Silva de Souza; Flavia da Cunha Vasconcelos; Luis Felipe R Silva; Raquel Ciuvalschi Maia
Journal:  Tumour Biol       Date:  2012-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.